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Abstract
Historically,  some  genetic  syndromes  and  monogenic  forms  of  obesity  have  been
identified by clinical features and by sequencing candidate genes in patients with severe
obesity. The phenotypic expression of genetic factors involved in obesity is variable,
thereby allowing to distinguish several clinical pictures of obesity. Monogenic obesity
is described as rare and severe early‐onset obesity with abnormal feeding behavior and
endocrine  disorders.  Many  of  the  findings  emerged  from  studying  families  who
displayed a classical Mendelian pattern of inheritance. On the contrary, patients with
syndromic obesity show a various degree of intellectual disability, different dysmorphic
features, and organ‐specific abnormalities. But to date, not all involved genes have been
identified so far. New diagnostic tools, such as genome‐wide studies, array CGH, and
whole‐exome sequencing, have highlighted more complex models of inheritance, and
even more candidate genes were identified. This increase of knowledge may provide
insights into the mechanisms involved in the regulation of body weight and finally lead
to specific treatments. In these patients, hyperphagia is often a primary phenotypic
component.  Substantial  gaps  in  understanding  the  molecular  basis  of  inherited
hyperphagia syndromes are present today with a lack of mechanistic targets that can
serve as  a  basis  for  pharmacologic  and behavioral  treatments.  We have evaluated
retrospectively the literature data on weight, body mass index (BMI), clinical features,
treatments, and treatment response in pediatric patients with forms of genetic obesity.
However, this chapter provides an updated picture of emerging knowledge outlined
by the more comprehensive genetic approaches, trying to outline more candidate genes
for these forms of genetic obesity. Relevant papers will be identified through systematic
searches of the PubMed, EMBASE and Cochrane databases. All published studies in the
English  language  concerning  these  disorders  will  be  evaluated.  Keywords  in  the
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literature search will be entered in all combinations. Searches will be augmented by
manually reviewing the reference lists of all original articles and all systematic review
articles, with each study being evaluated for inclusion.
Keywords: obesity, children, adolescence, next‐generation sequencing, array CGH,
pediatrics, diabetes, hyperphagia
1. Introduction
The World Health Organization defines being overweight and obesity as a “clinical condition
characterized by an abnormal or excessive fat accumulation that may impair health” [1]. In
2014, an estimated 41 million children under the age of 5 were overweight or obese [1]. Once
considered a problem only in high‐income countries, being overweight and obesity are now
dramatically on the rise in low‐ and middle‐income countries, particularly in urban settings [1].
Therefore, obesity is considered a global epidemic and can cause serious health repercussions.
In fact, in addition to causing a significant morbidity and premature mortality and to have
psychological and social consequences, it is associated with medical conditions, such as type
II diabetes (non‐insulin‐dependent diabetes mellitus or NIDDM), hypertension, coronary
artery disease and many forms of cancer [2].
In order to create the best management programs and to determine novel therapeutic targets,
it has become essential to understand the factors causing today's rising epidemic of childhood
obesity [3].
Obesity is a complex condition, caused by multiple factors. It is characterized by an altered
energy system, determined by the interaction of biological, social, and behavioral factors that
cause an increase in food intake and a reduction in energy expenditure [4].
This global epidemic and the increase of its prevalence show that this condition is the result
not only of genetic causes, but also of environmental factors (high availability of palatable and
energy dense foods) [4]. However, some individuals manage to maintain a healthy body weight
in an “obesogenic” environment, but the weight gain may be determined by their genetic
susceptibility [4].
Recently, major advances in obesity research emerged concerning the molecular mechanisms
contributing to the obese condition. However, several studies and data concerning the genetics
and other important factors in the susceptibility risk of developing obesity are became
increasingly evident [5]; in fact, available data suggest that 40–77% of the observed variance
in human body weight can be accounted for, by inherited factors [6–8].
The strongest risk factor for childhood and adolescent obesity is parental obesity [9]. The risk
becomes especially elevated if both parents are obese [10]. On the contrary, the pattern of
inheritance of monogenic obesity is different (which may or may not be related to specific
syndromes). In fact, they are attributable to a Mendelian model which recognizes a rare
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causative mutation to load a single gene that can be expressed in the heterozygous and
homozygous state [11].
Patients can be affected by monogenic forms, in which obesity is the predominant feature but
it is not associated with malformations, or by syndromic obesity: in the latter case, they show
also a pattern of clinical features, including developmental delay, dysmorphic features,
and/or other developmental abnormalities [12].
Furthermore, historically, some genetic syndromes and monogenic forms of obesity have been
identified by clinical features and by sequencing candidate genes in patients with severe
obesity. Many of the initial findings emerged from studying families who displayed a classical
Mendelian pattern of inheritance; however, more comprehensive genetic approaches, such as
genome‐wide studies, array CGH, and next‐generation sequencing examinations, have
highlighted more complex models of inheritance, and ever more candidate genes were
identified [13]. In broad terms, most cases of patients with genetic forms of obesity are
oligogenic, determined by interaction between genetic and environmental factors. In these
cases, the genetic make‐up influences weight and the individual responses to nutrition and
physical activity. In addition to this form of obesity, there are others caused by a single gene
or it appears to be related to a specific syndrome. Monogenic obesity typically is caused by a
single gene mutation with severe obesity as the main symptom; syndromic obesity, on the other
hand, has many characteristics, of which obesity is one symptom [13].
The increase of knowledge about the functional and physiological features of these different
obesity forms may provide insights into the mechanisms involved in the regulation of body
weight and finally lead to specific treatments. In these patients, hyperphagia is frequently a
primary phenotypic component. Substantial gaps in understanding the molecular basis of
inherited hyperphagia syndromes are present today with a lack of mechanistic targets that can
serve as a basis for pharmacologic and behavioral treatments.
The comprehension of the molecular mechanisms of obesity progressed enormously in the last
years thanks to the development of faster and more precise genetic screening tools applied in
cohort studies or in examinations with focus on subjects and their families.
Several clinical presentations in obesity depend on the genes involved:
1. Monogenic obesity, described as rare and severe early‐onset obesity, associated with
endocrine disorders. The impact of genetics is high and only little dependent on environ‐
mental factors.
2. Syndromic obesity that corresponds to severe obesity associated with additional pheno‐
types (mental retardation, dysmorphic features, and organ‐specific developmental
abnormalities). Prader‐Willi (PWS) and Bardet‐Biedl (BBS) syndromes are the two most
frequently linked to obesity, but more than 100 syndromes are now associated with
obesity.
3. Oligogenic obesity, characterized by a variable severity, partly dependent on environ‐
mental factors and the absence of a specific phenotype. This type of obesity is responsible
for 2–3% in adults and children.
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Rare genetic forms of obesity are important to be detected clinically because it allows to
progress in understanding the physiopathology of obesity. On the other hand, there is a specific
management of these forms of obesity provided by specialized and multidisciplinary teams.
2. Monogenic obesity
A “monogene” is by textbook definition, a gene with a strong effect on the phenotype (Men‐
delian traits or Mendelian—single gene conditions), giving rise to a one‐on‐one relationship
between genotype and phenotype.
So, monogenic and not syndromic obesity is caused by a single mutation of a gene.
This form of obesity occurs in infancy and is often associated with additional behavior,
developmental or endocrinological disabilities, such as hyperphagia and hypogonadism;
however, significant developmental delays are not visible, and the obesity is often not
associated with other clinical manifestations [3, 6, 8, 13–17].
The types of monogenic obesity are summarized in Table 1 [10–12, 18].
Monogenic obesity  Gene name  Main distinguishing features in addition to obesity
LEP deficiency LEP Hypogonadism, absent or delayed puberty, frequent infections, undetectable serum
leptin
LEPR deficiency LEPR Hypogonadism, absent or delayed puberty
SH2B2 deficiency SH2B1 Severe insulin resistance and disproportionate to degree of obesity; in rare cases
presence of developmental delay
POMC deficiency POMC Hypogonadism, absent or delayed puberty, hair and cute hypopigmentation, isolated
ACTH deficiency
MC4‐R deficiency MC4‐R Accelerated growth, increased final height
PCSK1 deficiency PCSK1 Hypogonadism, absent or delayed puberty, postprandial hypoglycemia, elevated
plasma proinsulin, severe malabsorption in the neonatal period
SIM1 deficiency SIM 1 Spectrum of developmental delay
BDNF/trkB
deficiency
BDNF o
NTRK2
Developmental delay, hyperactivity, impaired memory, impaired pain sensation
CART deficiency CART Anxiety and depression
Adapted with permission from Ramachandrappa and Farooqi [19].
Table 1. Main features of monogenic not syndromic obesity.
These types of monogenic obesity are caused by mutations in leptin–melanocortin hypothala‐
mic pathway genes. These genes regulate the sense of appetite and hunger (Figure 1).
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Figure 1. Appetite regulation: inhibitory (‐) and favoring (+) mechanisms. Adapted with permission from Perrone et al.
[11].
2.1. Congenital leptin deficiency (OMIM #614962)
In 1997, two severely obese cousins (an 8‐year‐old female child with a weight of 86 kg and a
2‐year‐old male child with a weight of 29 kg) were reported from a highly consanguineous
family of Pakistani origin [20]. Despite their severe obesity, both children had undetectable
levels of serum leptin and a mutation in the gene encoding leptin mapped at 7q32.1. The disease
is caused by mutations in the LEP gene (OMIM *164160) typically leading to defects in protein
synthesis or secretion, and therefore to the absence or very low blood levels of this hormone
[21–23].
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However, recently the first cases of functional leptin deficiency have been described [23, 24].
This entity is characterized by detectable immunoreactive levels of circulating leptin, but
bioinactivity of the hormone due to defective receptor binding [23, 24].
So, serum leptin may be a useful marker in patients with severe early‐onset obesity as an
undetectable serum leptin is highly suggestive of a diagnosis of congenital leptin deficiency
due to homozygous loss of function mutations in the LEP gene [12]. Leptin‐deficient subjects
are born of normal birth weight but exhibit rapid weight gain in the first few months of life
resulting in severe obesity [25].
Leptin deficiency causes the loss of appetite control, so it is associated with hyperphagia,
increased energy intake and aggressive behavior when food is denied. Other phenotypic
features include hypothalamic hypothyroidism, hypogonadotropic hypogonadism (because
leptin stimulates hypothalamic gonadotropin‐releasing hormone [GnRH] production),
elevated plasma insulin, T‐cell abnormalities (because leptin also stimulates the inflammatory
response and proliferation of T cells and cytokines Th1 mediated), and advanced bone age [26].
Currently, the prevalence of mutations in leptin is about 1% [12].
Leptin deficiency is entirely treatable with daily subcutaneous injections of recombinant
human leptin with beneficial effects on the degree of hyperphagia, reversal of the immune
defects and infection risk and permissive effects on the development of puberty [25]. The
major effect of leptin administration is the normalization of hyperphagia and enhanced satiety
[25, 27].
2.2. Congenital leptin‐receptor deficiency (OMIM #614963)
In 1998 (1 year after the discovery of the congenital leptin deficiency), patients with similar
phenotypic characteristic of leptin deficiency, but with a high blood level of leptin, were
reported [28]. In these patients, a mutation in the leptin receptor (LEPR, OMIM *601007),
mapped at 1p31.3, has been described [28].
One subsequent study has demonstrated that 3% of a group of patients with severe, early‐
onset obesity had a pathogenic LEPR mutation, but blood levels of leptin were not very high,
suggesting that blood leptin levels cannot be used as a marker for leptin‐receptor deficiency
[29].
In literature, many mutations of the leptin receptor are described. Most recently, three novel
mutations have been reported in the LEPR in two unrelated affected obese girls when latest
genetic analysis techniques like whole‐exome sequencing and targeted sequencing have been
used for the mutational analysis in this gene [30, 31].
The clinical phenotypes associated with congenital leptin‐receptor deficiency are similar to
those of leptin deficiency, with severe obesity from the first few months of the life, hypothala‐
mic hypothyroidism and hypogonadotropic hypogonadism [12, 26].
On the contrary, in these patients, because of a non‐functional LEPR, leptin treatment is
ineffective. Other factors could possibly bypass normal leptin delivery systems, but these are
not yet currently available for the treatment of these patients [32].
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2.3. SH2B1 deficiency
The Src‐homology‐2 B adaptor protein 1 (SH2B1, OMIM *608937) is a key intermediary in leptin
signaling, promoting the activation of the leptin signaling pathway downstream of Janus
kinase 2 (JAK2, OMIM *147796) [15]. So, leptin‐stimulated activation of hypothalamic JAK2 is
dramatically attenuated in SH2B1 knockout mice [33].
In 2010, it was described that the 220‐kb 16p11.2 deletion (28.73–28.95 Mb) seen in three
patients co‐segregated with severe early‐onset obesity alone [14]. This deletion includes a
small number of genes, one of which was SH2B1, known to be involved in leptin and insulin
signaling [12]. However, several mutations in the SH2B1 gene have also been reported in
association with early‐onset obesity, severe insulin resistance and behavioral abnormalities
in some patients [34].
The phenotype of the children with SH2B1‐containing deletions is characterized by extreme
hyperphagia and fasting insulin levels disproportionately elevated compared to age and
obesity‐matched controls [15]. As expected, obese SH2B1 KO mice develop hyperglycemia,
hyperinsulinemia, glucose intolerance, and insulin resistance and NIDDM [35]. Interestingly,
central and peripheral SH2B1 seem to regulate insulin sensitivity and glucose metabolism
independently of its action on body weight in man and mice [36].
In these patients, there is no specific treatment, but care must be taken in starting a specific
follow‐up on the hyperphagia, obesity and alteration of gluco‐insulinemic metabolism.
2.4. POMC deficiency (OMIM #609734)
In 1997, a role of central melanocortin signaling in the control of energy homeostasis was
known [37]. Proopiomelanocortin (POMC) acts on anorectic targets of leptin in the brain [38].
The POMC, through to proconvertase 1 (PCSK1), is the precursor of a‐melanocyte‐stimulating‐
hormone anorectic peptide (a‐MSH); the latter acts on melanocortin 4 receptor (MC4‐R)
anorectic neurons and suppresses the appetite and food intake [39].
Monogenic obesity from POMC deficiency manifests itself when there are homozygous null
mutations. Heterozygous carriers of null POMC gene mutations have a significantly higher
risk of being obese or overweight but are not invariably associated with obesity [19].
Since POMC is the precursor of adrenocorticotropic hormone (ACTH) and melanocyte‐
stimulating‐hormone anorectic peptide (MSH), POMC‐deficient newborns have adrenal crisis
and pale skin and hair. Also, POMC deficiency causes hyperphagia and childhood obesity [3,
40]. The clinical features are comparable to those reported in patients with mutations in the
receptor for POMC‐derived ligands, MC4R (see below in the next chapter) [12].
Two important POMC mutations have been described in literature: the first is the rare mutation
R236G that disrupts a di‐basic cleavage site between β‐MSH and β‐endorphin, resulting in a
β‐MSH/β‐endorphin fusion protein that binds to MC4R but has reduced ability to activate the
receptor [38, 41]. The second is a rare missense mutation in the region encoding β‐MSH,
Tyr221Cys that cannot bind to and activate signaling from the MC4R, and obese children
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carrying the Tyr221Cys variant are hyperphagic and showed increased linear growth, features
of MC4R deficiency [42].
Specific treatment was not available until January 2016, when the US Food and Drug Admin‐
istration awarded orphan drug status to the first α‐MSH‐based therapy for obesity. The α‐MSH
analog RM‐493 [43, 44], also known as setmelanotide, was awarded orphan drug status for
POMC deficiency and Prader‐Willi syndrome [37].
2.5. Melanocortin‐4 receptor deficiency (MC4R)
Among all forms of monogenic obesity, the most common is caused by MC4‐R deficiency.
Heterozygous mutations have been reported in many ethnic groups of obese patients and
prevalence varies from 0.5 to 1.0% in obese adults, up to 6% in individuals with severe infantile
onset obesity [45]. In 2014, a case of childhood obesity associated with compound hetero‐
zygosity for two mutations of MC4R gene (OMIM *155541), mapped at 18q21.32, was descri‐
bed [46]. In the same year, another new inactivating homozygous mutation of the MC4R gene
in a girl with the severe obesity and hyperphagia was reported [47].
Mutations of this gene are codominant with variable penetrance and expressivity in hetero‐
zygous carriers [48]. Both heterozygous and homozygous mutations in MC4R have been
implicated in obesity, but extreme obesity is incompletely penetrant in heterozygous patients
[3]. Also, in these patients, genetic and environmental factors influence the severity of obesity
associated with mutations of MC4‐R.
The main clinical features include hyperphagia in early appearance (but not as severe as that
seen in leptin deficiency) and an increase in fat mass, lean mass and bone mineral density [45].
These patients also have an accelerated growth that seems to be a consequence of hyperinsu‐
linemia which such patients present from the earliest periods of life. It is apparently not related
to a dysfunction of the GH axis [3, 49]. Despite this early hyperinsulinemia, obese adult subjects
who are heterozygous for mutations in the MC4R gene are not at increased risk of developing
glucose intolerance and NIDDM compared to controls of similar age and adiposity [12, 45].
Currently, there are no specific therapies for the MC4‐R deficiency, but these individuals may
benefit from surgical therapies, which could be taken into consideration in adults [12].
2.6. PCSK1 deficiency (OMIM #600955)
Pro‐protein convertases (PCs) are a family of serine endoproteases that cleave inactive pro‐
peptides into biologically active peptides [50]. Two of these pro‐protein, proprotein convertase,
subtilisin/kexin‐type 1 (PCSK1) and PCSK2 are selectively expressed in neuroendocrine tissues
and cleave pro‐hormones such as POMC, thyrotropin‐releasing hormone (TRH), GnRH,
proinsulin, proglucagon [12].
Patients with heterozygous or homozygous mutations in the PCSK1 gene (OMIM *162150),
mapped at 5q15, present small bowel enteropathy, early‐onset obesity and complex neuroen‐
docrine effects due to a failure to process the pro‐hormones such as diabetes insipidus,
glucocorticoid deficiency, hypogonadism, and altered glucose homeostasis [51, 52].
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A typical characteristic of these patients is a history of severe intestinal malabsorption in the
neonatal period, probably due to altered cleavage of intestinal peptides in the enteroendocrine
cells [51].
Over the past few years, two meta‐analysis about PCSK1 mutations have been published: the
first in 2014 confirmed the association of PCSK1 SNPs with obesity and provides the first
evidence that the association between PCSK1 rs6232 and obesity is stronger for childhood
obesity than for adult obesity; the second meta‐analysis tried to study the association of PCSK1
variants rs6232 and rs6234/rs6235 with quantitative BMI variation and common obesity risk in
subjects from diverse ethnic groups. In this study, cohort age‐group significantly modulated
the association between rs6232, rs6234/rs6235 and obesity with the effect sizes for both SNPs
being stronger in children/adolescents than in adults.
It is thought also that the most common PCSK1 variants predispose to obesity especially in an
“obesogenic” environment with free access to high‐caloric food [53].
Currently, there are no specific therapies for the PCSK1 deficiency, but these individuals
frequently required a prolonged course of parenteral nutrition therapy, particularly in the first
year of life [54]. However, exogenous administration of several hormone may be necessary in
relation to the hormonal deficiencies diagnosed [54].
Figure 2. Girl with 6q16.3 deletion involving SIM1 gene. It is evident that the extreme increase of the BMI of the patient
and the reduction after the interdisciplinary approach.
2.7. SIM1 deficiency
Single‐minded 1 (SIM1) is a transcription factor involved in the development of the supraoptic
and paraventricular nuclei, acting downstream signal cascade of MC4‐R. Obesity and
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hyperphagia have been reported in a patient with a balanced translocation disrupting SIM1
[55] and multiple heterozygous missense mutations (6q16.3; OMIM *603128) [56]. However,
some mutations of SIM1 have incomplete penetrance and variable phenotype [57]. The similar
phenotype between patients with SMI1 and MC4‐R deficiency suggests that some effects of
SIM1 are mediated by altered melanocortin signaling. On the other hand, some children with
SIM1 mutations have neuro‐behavioral disorders including autism spectrum and “Prader‐
Willi‐like” phenotype (Figure 2) [3, 12].
In mice, hyperphagia associated with SIM1 deficit can be improved by the administration of
oxytocin, a neurotransmitter involved in the modulation of emotion (impaired oxytocinergic
signaling is also one possible mechanism implicated in the obesity) [58].
2.8. Other types of non‐syndromic genetic obesity
Mutations of the BDNF (brain‐derived neurotrophic factor, OMIM *113505, mapped at 11p14.1)
and its receptor TrKb (tyrosin kinase B receptor, OMIM *600456, mapped at 9q21.33) are rare
causes of monogenic obesity acting downstream signal cascade of MC4‐R and blocking
translation [59].
BDNF's role in energy homeostasis emerged in the 1990s with the observation that intracere‐
broventricular BDNF administration suppresses appetite and induces weight loss in ro‐
dents, and Bdnf heterozygous knockout mice exhibit hyperphagia and obesity [60]. Complete
lack of BDNF during embryologic development is perinatally lethal, but haploinsufficiency
for BDNF or inactivating mutations of the BDNF receptor was associated with increased ad
libitum food intake, severe early‐onset obesity, hyperactivity, and cognitive impairment [60,
61]. Multiple genome‐wide association studies of obesity in children and adults of different
racial and ethnic populations have found associations for single‐nucleotide polymorphisms
(SNPs) at the BDNF locus and BMI, in particular for G196A variant (rs6265), which leads to a
valine to methionine substitution at the 66th amino acid position (Val66Met) of the N‐terminal
prodomain of pro‐BDNF. Furthermore, modifying factors—particularly sex, lifestyle behav‐
iors, and psychotropic medication use—appear to be important confounders for the associa‐
tion between rs6265 and BMI [60–62]. In addition, the minor C allele of intronic rs12291063
SNP was associated with lower BDNF expression and higher BMI [63].
NTRK2 (TrkB) mutation (which interferes with receptor autophosphorylation) causes the same
symptoms of BDNF deficiency such as hyperphagia, obesity, impaired nociception, and
intellectual disability [64, 65]. Recently, a de novo mutations in TrkB was found in a boy with
severe obesity and impairment in learning, memory and nociception, and in a girl with
hyperphagia and severe obesity [66].
Another cause of non‐syndromic monogenic obesity is due to a gene mutation of CART
(cocaine‐ and amphetamine‐regulated transcript, OMIM *602606), mapped at 5q13.2. CART is an
anorexigenic peptide produced by specific hypotalamic neurons in response to the stimulus
of leptin. It would appear to mediate the termogenetic effects and energy expenditures
characteristic of leptin. It has been shown that mutations in the CART gene are associated with
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reduced levels of the peptide encoded by it. Adolescents carrying a missense mutation in the
CART gene exhibit severe obesity associated with anxiety and depression [11, 67, 68].
Other recent forms of monogenic obesity, still being defined, are associated with MRAP2
(melanocortin 2 receptor accessory protein 2, OMIM *615410, mapped at 6q14.2) mutation encod‐
ing a MC4‐R co‐receptor, and with KSR2 (Kinase suppressor of Ras 2. OMIM *610737, mapped
at 12q24.22‐q24.23) mutation, a protein involved in intracellular signal with a role in energy
homeostasis [69–72].
3. Syndromic obesity
To date have been identified syndromic forms (e.g., Prader‐Willi Syndrome) in which obesity
can be associated with other signs and symptoms, such as intellectual disability, dysmorfic
features and unusual behaviors.
In these syndromes, obesity can be caused by hyperphagia because are involved genes related
to central nervous system appetite control centers.
Recently, the genetic bases for some of these syndromes have been elucidated and are begin‐
ning to provide insights into the pathogenesis of the derangements of energy homeostasis.
Table 2 reports the main syndromic forms of obesity. High‐throughput technologies, and in
particular copy number variants (CNVs) detection, are likely to result in the identification and
recognition of multiple new syndromes where obesity and developmental delay are closely
associated [12].
Syndrome  Clinical features in addition to
obesity 
Prevalence  Genetic 
Bardet‐Biedl  Mental retardation, retinal
dystrophy or pigmentary retinopathy,
dysmorphic extremities,
hypogonadism, kidney anomalies 
1/125,000 to
1/175,000 births 
BBS1 (11q13); BBS2 (16q12.2);
BBS3 (ARL6, 3q11); BBS4
(15q24.1); BBS5 (2q31.1); BBS6
(MKKS, 20p12); BBS7 (4q27); BBS8
(TTC8, 14q31); BBS9 (PTHB1,
7p14); BBS10 (C12ORF58,
12q21.2); BBS 11 (TRIM32,
9q33.1); BBS12 (FLJ35630, 4q27);
BBS13 (MKS1, 17q23); BBS14
(CEP290, 12q21.3); BBS15
(WDPCP, 2p15); BBS16
(SDCCAG8, 1q43); BBS17
(LZTFL1, 3p21); BBS18 (BBIP1,
10q25); BBS19 (IFT27, 22q12) 
Prader‐Willi  Neonatal hypotonia, mental
retardation, hyperphagia,
1/25,000 births  Lack of the paternal segment
15q11‐q13 (microdeletion,
maternal disomy, imprinting
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Syndrome  Clinical features in addition to
obesity 
Prevalence  Genetic 
facial dysmorphy, hypogonadotrophic
hypogonadism, short stature 
defect or reciprocal
translocation) 
Cohen  Retinal dystrophy, prominent central
incisors, dysmorphic extremities,
microcephaly, cyclic neutropenia 
Diagnosed in fewer
than 1000 patients
worldwide 
Autosomal recessive COH1 gene
(chr 8q22‐q23) 
Alström  Retinal dystrophy, neurosensory
deafness, diabetes, dilated
cardiomyopathy 
Diagnosed in about
950 patients
worldwide 
Autosomal recessive ALMS1 gene
(chr 2p13‐p14) 
X fragile  Mental retardation, hyperkinetic
behavior, macroorchidism, large ears,
prominent jaw 
1/2500 births  X‐linked FMR1 gene (Xq27.3) 
Borjeson‐Forssman‐
Lehmann 
Mental retardation, hypotonia,
hypogonadism, facial dysmorphy with
large ears, epilepsy 
Approximately 50
reported patients 
X‐linked PHF6 gene (Xq26‐q27) 
Albright hereditary
osteodystrophy 
Short stature, skeletal defects, facial
dysmorphy, endocrine anomalies 
1/1,000,000 births  Autosomal dominant GNAS1
gene (20q13.2) 
Ulnar–mammary  Upper limb malformation (from
hypoplasia of the terminal phalanx of
the fifth digit to aplasia of hand and
upper limbs on the ulnar side), abnormal
development of mammary glands and
nipples, teeth, genitalia, and of apocrine
glands 
  Autosomal dominant TBX3 gene
(12q24.21) 
Simpson‐Golabi‐
Behmel 
Multiple congenital abnormalities, pre‐/
post‐natal overgrowth, distinctive
craniofacial features, macrocephaly, and
organomegaly. 
  X‐linked GPC4 gene (Xq26) 
MEHMO
syndrome 
Mental retardation, epileptic seizures,
hypogenitalism, microcephaly and
obesity 
Approximately
<1/1,000,000 births 
X‐linked locus MEHMO
(Xp22.13‐p21.1) 
1p36 deletion
syndrome 
Delayed growth, malformations,
moderate to severe intellectual
disability, seizures, hearing and
vision impairment, and certain
particular facial features. 
1/5000 to 1/10,000
live births 
Autosomal dominant
microdeletion of 1p36 
16p11.2 deletion
syndrome 
Developmental delay, intellectual
disability, autism spectrum disorders,
impaired communication, socialization
skills 
Approximately
3/10,000 births 
Autosomal dominant
microdeletion of 16p11.2 
ACP1, TMEM18,
MYT1L deletion 
Hyperphagia, intellectual deficiency,
severe behavioral difficulties 
Approximately 13
reported patients 
Paternal deletion encompassing
the ACP1, TMEM18, MYT1L
genes (2p25) 
Table 2. Main forms of syndromic obesity.
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3.1. Developmental obesity syndromes involving ciliary dysfunction
Some genes linked to obesity have been associated with the function or formation of primary
cilia, subcellular organelles, which serve a sensory function for most cell types. The ciliopathies
form a class of genetic disease whose etiology lies with primary ciliary dysfunction. Some
peculiar features can be found, such as retinal degeneration. This feature is of particular interest
for its clinical relevance, rarity, and diagnostic power. Between these groups of diseases, we
can include the Bardet‐Biedl syndrome (BBS) and Alström syndrome (ALMS).
BBS has become a model ciliopathy because it became the first disease whose etiology lay in
primary ciliary disorder [73]. It is a rare autosomal recessive genetic disorder with severe
multiorgan impairment [74]. Its frequency in Europe and North America falls below 1:100,000
[75]. The disease symptoms may significantly vary between the patients; therefore, the
diagnosis relies on the number of primary and secondary features of BBS [74]. Multiple articles
summarize the data on frequencies of various symptoms in BBS patients [75, 76]. However, it
is very important to realize that almost all clinical studies analyzed patients of various ages.
Many individuals with BBS look virtually healthy at birth unless they were born with a
polydactyly. Other symptoms of BBS tend to gradually emerge during or after the first decade
of life; thus, patients diagnosed at early childhood tend to have fewer clinical features of the
disease [74]. There are six primary features of BBS, that is, rod‐cone dystrophy, polydactyly,
obesity, genital abnormalities, renal defects, and learning difficulties. Secondary features
include developmental delay, speech deficit, brachydactyly or syndactyly, dental defects,
ataxia or poor coordination, olfactory deficit, diabetes mellitus, and congenital heart disease
[75]. Some authors also mention hypertension, liver abnormalities, bronchial asthma, otitis,
rhinitis, craniofacial dysmorphism, etc. [75–78].
However, the phenotype can be different: generally, obesity occurs early in life of patients
affected by BBS, but the literature shows that 52% of post‐pubertal BBS patients are obese [79].
It is recommended to assign BBS diagnosis to patients bearing at least 4 out of 6 primary
features of the disease. If only three primary features are detected, two secondary features are
required to confirm the presence of BBS.
These criteria describe BBS mainly as a clinical entity; they do not fully account to the existence
of patients with attenuated forms of the disease as well as to possible gene‐specific manifes‐
tations of BBS [80, 81].
At least 20 BBS genes have already been identified, and all of them are involved in primary
cilia functioning. Genetic diagnosis of BBS is complicated due to lack of gene‐specific disease
symptoms; however, it is gradually becoming more accessible with the invention of multigene
sequencing technologies [74].
The first five BBS loci were identified via linkage analysis of large BBS pedigrees [82–86] with
corresponding genes cloned some years later [87–92]. The first gene assigned to BBS was MKKS
(MKS; OMIM *604896) already known to induce McKusick‐Kaufman syndrome; given that it
did not belong to previously identified BBS loci, it was named BBS6. At present, there are
already 21 known BBS genes (BBS1–BBS20 and NPHP1), and their number is likely to increase
due to the invention of exome sequencing and analysis of previously unstudied populations
New Thoughts on Pediatric Genetic Obesity: Pathogenesis, Clinical Characteristics and Treatment Approach
http://dx.doi.org/10.5772/66128
225
[74]. Strikingly, all BBS genes participate in cilia functioning, being a part of BBSome (BBS1
[11q13.2; OMIM *209901], BBS2 [16q13; OMIM *606151], BBS4 [15q24.1; OMIM *600374], BBS5
[2q31.1; OMIM *603650], BBS7 [4q27; OMIM *607590], BBS8 [14q31.3; OMIM *608132], BBS9
[7p14.3; OMIM *607968], BBS17 [3p21.31; OMIM *606568], and BBS18 [10q25.2; OMIM
*613605]); chaperonin complex (BBS6 [20p12.2; OMIM *604896], BBS10 [12q21.2; OMIM
*610148], and BBS12 [4q27; OMIM *610683]); basal body (BBS13 [17q22; OMIM *609883], BBS14
[12q21.32; OMIM *610142], BBS15 [2p15; OMIM *613580], and BBS16 [1q43‐q44; OMIM
*613524]) or having some related biological function (BBS3 [3q11.2; OMIM *608845], BBS11
[9q33.1; OMIM *602290], BBS19 [22q12.3; OMIM *615870], BBS20, and NPHP1 [2q13; OMIM
*607100]) [74].
Many of these genes appear to affect proteins localized to the basal body, a key element of the
monocilium thought to be important for intercellular sensing in mammalian cells including
neurons [73]. The literature shows that ciliary function is associated with leptin signaling [93].
As evidenced by some studies in mice, hyperphagia and obesity are caused by conditional
post‐natal knockout of proteins involved in intraflagellar transport [94], but they occur also
when the loss of cilia affects the neurons, in particular POMC neurons [94].
Alström syndrome (ALMS; OMIM #203800) is a rare genetic disorder that has been included
in the ciliopathies group, in the last few years [95].
The estimated prevalence for ALMS is one to nine cases per 1,000,000 individuals with nearly
900 cases described worldwide to date. Symptoms first appear in infancy and progressive
development of multi‐organ pathology lead to a reduced life expectancy. Variability in age of
Figure 3. BMI growth chart in a girl with Alström syndrome.
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onset and severity of clinical symptoms, even within families, are likely due to genetic back‐
ground [95].
Children typically develop obesity by age 5 years, associated with hyperinsulinemia, chronic
hyperglycemia and neurosensory deficits (Figure 3) [6]. Children affected by ALMS, like
children with BBS, have visual impairment and deafness that occurs early in life but its
incidence is higher in these patients as well as NIDDM, found in up to 70% of individuals by
age 20 years [96, 97].
In addition, ALMS is also associated with cardiomyopathy, renal anomalies and endocrino‐
pathies such as hypertriglyceridemia, pubertal delay, and hyperandrogenism and growth
hormone deficiency [97].
Until now, disease‐causing mutations in the ALMS1 (2p13.1; OMIM *606844) gene have been
involved in this disorder.
The diagnosis is based on the phenotype of the patient, and it is confirmed when two muta‐
tions in ALMS1 gene are identifies through molecular analysis.
However, it is difficult to diagnose early ALMS first of all because symptoms arise gradually
and secondly because the phenotypes overlap, in particular with BBS in the case of ALMS [98].
In recent times, thanks to the discovery of new genetic tools, in particular next‐generation
sequencing (NGS) technology, a large number of patients have been diagnosed. The advent of
these new techniques allows early diagnosis also in those patients who do not have a charac‐
teristic phenotype, thus preventing long‐term complications that can be caused by a delay in
diagnosis [99].
Today, the most used genetic techniques are whole‐exome sequencing (WES) and whole‐
genome sequencing, thanks to their low cost. However, they are also important because they
allow to exclude the mutations in other genes [99, 100].
The WES is a rapid and easier technique because it analyzes all coding regions in the genome
[100]. Thanks to it, in fact, mutations in ALMS1 gene have been identified in individuals, whose
phenotype did not seem to be typical of ALMS; therefore, it is fundamental to identifying
pathogenic mutations in compound heterozygous state in ALMS1 gene, overcoming also
limitation of genetic panels in patient suffering from familial dilated cardiomyopathy and
severe heart failure [101].
In fact, as reported in literature, the association of WES and a previous linkage analysis has
allowed to identify the pathogenic mutations in ALMS1 gene in a consanguineous Turkish
family with severe dilated cardiomyopathy although it did not present the typical phenotype
of ALMS [102].
Moreover, these mutations have been shown also in consanguineous Leber congenital
amaurosis families through homozygosity mapping followed by WES [103].
As evidenced by these studies, the simultaneous use of different genetic techniques is funda‐
mental both in the case of consanguineous families that in patients without the typical ALMS
phenotype [95].
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For management of the disease and to identify an accurate treatment, it is important for both
the present of typical clinical features that an appropriate genetic diagnosis, which may be
carried out by NGS techniques, thanks to its low cost compared with traditional polymerase
chain reaction and direct Sanger sequencing [103].
4. Imprinted genetic syndromes
Prader‐Willi syndrome (PWS, OMIM #176270) is a disorder caused by errors in genomic
imprinting, which generally occur during both male and female gametogenesis. In particular,
there is the loss of expression of paternal genes normally active and located in the chromosome
15q11‐q13 region [104–108]. Conversely, a loss of expression of the preferentially maternally
expressed UBE3A (OMIM *601623) gene in this region leads to Angelman syndrome (AS;
OMIM #105830), an entirely different clinical disorder that causes developmental disabilities
and neurological problems, such as difficulty speaking, balancing and walking, and, in some
cases, seizures [109, 110].
According to several studies, most individuals with PWS (about two‐thirds) have a de novo
paternally inherited deletion of the chromosome 15q11‐q13 region; about 25% of cases have
maternal disomy 15 (chromosome 15 is inherited from the mother) [111]; less than 3% of
patients have defects in the genomic imprinting center due to microdeletions or epimutations
[104, 106, 112, 113], while rearrangements of the 15q11‐q13 region or chromosomal transloca‐
tions are rare [104, 114].
However, this syndrome, whose prevalence is around of 1/10,000–1/30,000, is considered the
most common cause of syndomic obesity [115].
The cardinal features of PWS include infantile hypotonia, feeding difficulties due to a poor
suck and failure to thrive (FTT), followed in later infancy or early childhood by excessive
appetite with gradual development of obesity, short stature and/or decreased growth velocity
due to growth hormone (GH) deficiency, intellectual disabilities (average IQ of 65), behavioral
problems (e.g., temper tantrums, outburst and skin picking) and particular facial appearance
(e.g., a small upturned nose, narrow bifrontal diameter with almond‐shaped eyes, down‐
turned corners of the mouth with sticky salivary secretions and generally lighter skin, hair
and eye color than other family members) [105, 106]. Hypothalamic dysfunction has been
implicated in many manifestations of this syndrome including hyperphagia, temperature
instability, high pain threshold, sleep‐disordered breathing and multiple endocrine abnor‐
malities [105, 107, 108].
Initially, two nutritional phases have been described in children with PWS:
• phase 1: the individual often presents FTT; he exhibits hypotonia with difficult feeding;
• phase 2: the individual is hyperphagic, and this condition will lead to obesity [105, 108].
To date, instead, seven different nutritional phases (five main phases and sub‐phases in phases
1 and 2) have been identified.
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As following, focusing on nutrition, although in the early phases, the child has poor appetite,
the latter increases in phase 2b and leads progressively to hyperphagia, evident in phase 3
(Table 3).
Phases Median ages  Clinical characteristics 
0  Prenatal to birth  Decreased fetal movements and lower birth weight than sibs 
1a  0–9 months  Hypotonia with difficulty feeding and decreased appetite. Needs assistance with
feeding either through feeding tubes [nasal/oral gastric tube or gastrostomy tube] or
orally with special, widened nipples 
1b  9–25 months  Improved feeding and appetite and normal growth 
2a  2.1–4.5 years  Weight increasing without appetite increase or excess calories. Will become obese if
given the recommended daily allowance [RDA] for calories. Typically needs to be
restricted to 60–80% of RDA to prevent obesity 
2b  4.5–8 years  Weight and appetite are increased but can feel full 
3  8 years to adulthood Hyperphagic, rarely feels full 
4  Adulthood  Appetite is no longer insatiable 
Adapted with permission from Cassidy et al. [107].
Table 3. Clinical characteristics of the nutritional phases seen in Prader‐Willi syndrome.
Analyzing the seven phases, we highlight the following:
• phase 0: the infant has growth restriction and decreased fetal movements;
• sub‐phase 1a: the infant is hypotonic with difficulty feeding and with or without FTT;
• sub‐phase 1b: the infant grows normally, and he improves appetite, also if weight gain is
normal;
• sub‐phase 2a: the child has a weight gain although there is not an increased appetite or
caloric intake;
• sub‐phase 2b: in addition to weight gain, there is an increased appetite;
• phase 3: the individual is hyperphagic; he seeks foods and presents the loss of sense of
satiety;
• phase 4: it is typical of adults, who have an insatiable appetite and are able to feel full [107].
As said previously, individuals with PWS present an appetite that gradually increases and
leads to obesity. In recent years, some studies have been conducted to understand the mech‐
anisms controlling appetitive behavior, energy expenditure and body composition.
The central nervous system, in particular the hypothalamus that determines changes in energy
balance, is involved in these processes.
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One of the determining factors for the development of obesity in these patients is ghrelin, a 28
amino acid peptide produced in the stomach, that transmit satiety signal and whose level in
obese PWS individuals is high [116, 117]. Circulating ghrelin levels are elevated in young
children with PWS long before the onset of hyperphagia, especially during the early phase of
poor appetite and feeding [118].
The literature reports that about 25% of the adults with PWS presents NIDDM (non‐insulin‐
dependent diabetes mellitus) [119]; however, some studies show that in PWS, children fasting
insulin concentrations and homeostasis model assessment insulin resistance index are lower
than in obese control [120].
This syndrome, as mentioned, represents an human disorder related to genomic imprinting.
Although the DNA sequence of the imprinted maternally and paternally inherited alleles is
the same, multiple epigenetic factors (such as DNA methylation, histone modifications and
chromatin conformation) ultimately will determine whether the imprinted allele is expressed
or repressed [121, 122].
DNA methylation analysis is the most efficient way to start the genetic workup if PWS is
suspected clinically, but it cannot distinguish the molecular class (i.e., deletion; uniparental
disomy, UPD; or imprinting defect, ID). Therefore, once the diagnosis of PWS is established
by DNA methylation analysis, determination of the molecular class is the next step.
There are different genetic testing used in PWS: CMA‐SNP array or FISH (fluorescence in situ
hybridization) for deletion of 15q11.2‐q13, DNA polymorphism analysis for UPD or ID or
testing with MS‐MLPA analysis for an IC deletion, important for the diagnosis of both of these
individuals who do not have sufficient features because they are too young than of those who
do not exhibit the typical phenotype [107].
4.1. Cohen syndrome
Cohen syndrome (CS) is an inherited disorder characterized by developmental delay, intel‐
lectual disability, microcephaly and hypotonia. Other features include progressive myopia,
retinal dystrophy, hypermobility and distinctive facial features [6, 12]. Characteristic facial
features include thick hair and eyebrows, long eyelashes, down‐slanting and wave‐shaped, a
bulbous nasal tip, a smooth or shortened philtrum, and prominent upper central teeth [6, 12].
Children with CS tend to manifest failure to thrive in infancy and early childhood but
subsequently become significantly overweight in the late childhood and adolescence. The
obesity tends to be truncal in nature [6, 12]. In contrast to PWS, appetite and food intake are
not increased during this time period, and activity is not noticeably decreased. Among
individuals with CS, the prevalence of short stature is approximately 65% and delayed puberty
74%; clinical endocrinologic evaluations did not identify explanations for these findings [6, 12].
4.2. 1p36 deletion syndrome
1p36 deletion syndrome is a disorder characterized by severe intellectual disability, hypotonia,
heart defects, hearing impairment and typical craniofacial features. In fact, patients with this
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syndrome show straight eyebrows, deeply set eyes, midface hypoplasia, broad and flat nasal
root/bridge, long philtrum, pointed chin, large, late‐closing anterior fontanel, microbrachyce‐
phaly, epicanthal folds and posteriorly rotated, low‐set, abnormal ears. Other typical findings
include brachy/camptodactyly and short feet. Developmental delay and intellectual disability
of variable degree are present in all, and hypotonia in 95%. Seizures occur in 44–58% of affected
individuals. Other findings include prenatal‐onset growth deficiency, structural brain abnor‐
malities, congenital heart defects, vision problems, deafness, skeletal anomalies, abnormalities
of the external genitalia and renal abnormalities. Obesity, which occurs as the consequence of
hyperphagia, is also frequently observed in patients with the 1p36 deletion syndrome [123].
In this recent report [124], 40% of patients had obesity and hypercholesterolemia, and 1 patient
developed NIDDM. Some authors suggested candidate regions for hyperphagia and obesity,
such as PRKCZ, that may be associated with obesity because this gene is involved in carbo‐
hydrate or lipid metabolism, or insulin signaling [123]. It is suggested that genetic or environ‐
mental factors more likely contribute to the development of obesity and DM. However, a subset
of patients may become overweight and obese with hyperphagia and NIDDM [125]. Previous
studies observed that obesity was found exclusively in female patients with 1p36 deletion who
showed growth restriction during the fetal period [126]. Because patients with 1p36 deletion
show hypotonia and hyperphagia with obesity and NIDDM, which are also characteristic
features of patients with PWS, some patients with 1p36 deletion may be misdiagnosed as
having PWS.
4.3. 16p11.2 deletion syndrome
16p11.2 microdeletion syndrome is a chromosomal anomaly characterized by developmental
and language delays, intellectual disability, social impairments represented by autism
spectrum disorders, variable dysmorphisms and predisposition to obesity. In fact, in a
screening cohort of patients with extreme obesity, enriched for patients with birth defects and/
or neurocognitive deficiencies using method to detect copy number variations, recurrent, de
novo deletions of 16p11.2 were identified in approximately 3% of cases. In these patients,
durable weight loss has not been reported. So durable weight control is recommended
although no data are available on the efficacy of early intervention in deletion carriers.
However, impaired cognition may also result in abnormal eating behavior contributing to the
obesity [127, 128]. Some data seem to hypothesize that this deletion may affect the neural
circuitry involved in the energy balance. The early increase in head circumference seems to
precede the onset of obesity [129]. The 16p11.2 deletion includes the SH2B1 gene, an adaptor
protein involved in leptin and insulin signaling which may be involved in the pathogenesis of
the obesity and insulin resistance observed in this deletion [130].
Additionally, deficiencies of SIM1 (single minded), BDNF (brain‐derived neurotrophic factor)
and NTRK2 (neurotrophic tyrosine receptor kinase encoding the TrK protein, the receptor for
BDNF) genes are associated with syndromic conditions involved in the functioning of the
hypothalamus downstream of MC4R‐expressing neurons and leading severe hyperphagic
obesity. For example, haplodeficiency of BDNF has also been implicated in the obesity occur‐
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ring in a subset of patients with WAGR (Wilms tumor, aniridia, genitourinary malformations
and retardation) syndrome [62].
4.4. Oligogenic obesity
Oligogenic obesity or common obesity is the result of the set of behavioral, environmental and
genetic factors that may influence individual responses to diet and physical activity [131]
(Figure 4).
Figure 4. Gene–environment interactions in common obesity. Adapted with permission from Mutch and Clément
[131].
The obesogenic changes of our environment in recent decades, especially the unlimited supply
of cheap food with high palatability and high energy density, associated with genetic suscept‐
ibility are the causes of the current obesity epidemic [132].
The recent rapid rise in prevalence of childhood obesity suggests that, probably, environmental
factors have a large impact on body weight in patients with common obesity although
individual responses to these environmental factors are influenced by genetic factors called
susceptibility genes [3].
Any of a group of alleles, at distinct gene loci that collectively control the inheritance of a
quantitative phenotype or modify the expression of a qualitative character, are termed
“polygenic” variants. A polygenic variant by itself has a small effect on the phenotype; only
in combination with other predisposing variants does a sizeable phenotypic effect arise.
Potentially, many such polygenic variants play a role in body weight regulation. It is estimated
that the total number of genes with a small effect most likely exceeds [133]. These genes are
involved in a variety of biological functions such as the regulation of food intake, energy
expenditure, carbohydrate and lipid metabolism and adipose tissue development [131].
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Therefore, unlike monogenic obesity, many genes and chromosome regions contribute to
common obesity phenotype.
Genome‐wide association studies have identified genetic risks for obesity. In less than 4 years,
52 genetic loci have been identified to be unequivocally associated with obesity‐related traits
[134]. However, these loci have only small effects on obesity susceptibility and explain just a
fraction of the total variance. As such, their accuracy to predict obesity is poor and not
competitive with the predictive ability of traditional risk factors such as parental and childhood
obesity. The first convincing GWAS discovery for any obesity‐related trait was made in 2007
for BMI when the FTO locus was found to be associated with obesity‐related traits and
specifically with extreme and early‐onset obesity in children and adolescents [134–136].
Following the discovery of the FTO locus, one new locus near the MC4R was identified, a gene
in which mutations are known to be the commonest cause of extreme childhood obesity. Also
in recent years, other new BMI‐associated loci were discovered such as near TMEM18
(transmembrane protein 18, OMIM *613220, 2p25.3), near KCTD15 (potassium channel tetrameri‐
zation domain‐containing protein 15, OMIM *615240, 19q13.11), near GNPDA2 (glucosamine‐6‐
phosphate deaminase 2, OMIM *613222, 4p12), in SH2B1 (SH2B adaptor protein 1, OMIM *608937,
16q11.2), in MTCH2 (mitochondrial carrier homolog 2, OMIM *613221, 11p11.2), near NEGR1
(neuronal growth regulator 1, OMIM *613173, 1p31.1), near FAIM2 (FAS apoptotic inhibitory
molecule 2, OMIM *604306, 12q13.12), near SEC16B (SEC16, homolog of S. cerevisiae B, OMIM
*612855, 1q25.2), near ETV5 (ETS variant gene 5, OMIM *601600, 3q27.2) and in BDNF (brain‐
derived neurotrophic factor, OMIM *113505, 11p14.1). Although for many of these loci, associa‐
tion with BMI has been observed in children and in adolescents [64, 137], and in populations
of non‐white origin, their replication has been less consistent than for the FTO and near‐MC4R
loci for relatively small sample size of the replication studies [134].
Furthermore, longitudinal studies have been published in recent years that have followed up
children over time; these studies indicated that GWAS‐discovered risk variants influence the
development of obesity in part by accelerating weight gain during infancy and childhood [138–
140], but the mechanisms by which this occurs are not yet fully elucidated. One of the mech‐
anisms involved may be the different sense of appetite, but the results of the studies are
controversial [141, 142].
5. Epigenetics and obesity
Heritability estimates of BMI from twin studies range from 50 to 90% [143], so it plays a
fundamental role in determining body weight. However, this latest figure appears in con‐
tradiction to the evidence of an epidemic increase in pediatric obesity over the last 20 years,
time totally inadequate to record permanent changes in the genome. Only the reprogram‐
ming of gene expression through epigenetic modifications resulting from relevant environ‐
mental changes that have taken place mostly in the early periods of life may partially
justify this phenomenon [11]. Epigenetic regulation of gene expression emerged in the last
few years as a potential factor that might explain individual differences in obesity risk
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[144]. Epigenetics can be defined as heritable changes that are mitotically stable (and poten‐
tially meiotically) and affect gene function but do not involve changes in the DNA se‐
quence [145].
Currently, there is a growing interest in the study of the relationship between genetic variation,
epigenetic variation and disease simultaneously. The two main mechanisms that lead to
epigenetic changes are DNA methylation, and the alterations to histone proteins that alter the
likelihood that specific genes are transcribed [146, 147].
Interindividual variations in epigenetic changes like CpG methylation can potentially alter
gene function and predispose to obesity. The variation in the degree of methylation, in fact, is
able to modulate the expression of genes involved in controlling hypothalamic appetite [148].
Using a genome‐wide approach, obesity has been related to changes in DNA methylation
status in peripheral blood leukocytes of lean and obese adolescents for two genes: in the
UBASH3A (ubiquitin‐associated and SH3 domain‐containing protein A, OMIM *605736, 21q22.3)
gene, a CpG site showed higher methylation levels in obese cases, and one CpG site in the
promoter region TRIM3 (tripartite motif‐containing protein 3, OMIM *605493, 11p15.4) gene,
showed lower methylation levels in the obese cases [149]. Also the obesity risk allele of FTO
has been associated with higher methylation of sites within the first intron of the FTO gene,
suggesting an interaction between genetic and epigenetic factors [150]. In addition, the obesity
risk allele of FTO affects the methylation status of sites related to other genes (KARS [16q23.1;
OMIM *601421], TERF2IP [16q23.1; OMIM *605061], MSI1 [12q24.31; OMIM *603328], STON1
[2p16.3; OMIM *605357] and BCAS3 [OMIM *607470]), showing that the FTO gene may
influence the methylation level of other genes [151]. Finally, a recent work has demonstrated
that hypermethylation of the POMC gene plays an important role in preparing to obesity by
reducing the expression of the gene itself [148].
Epigenetic changes usually occur during prenatal development or the early post‐natal
period. Already in utero, in fact, there may be a switch of energy balance resulting from
exposure to specific environmental factors, resulting in epigenetic changes that can affect the
potential of the fat mass of offspring. For example in a recent work, the methylation status of
CpG from five candidate genes in umbilical cord tissue DNA from healthy neonates was
measured, and it was found that higher methylation levels within promoter region of RXRA
(retinoid X receptor, alpha, OMIM *180245, 9q34.2) gene, measured at birth, were strongly
correlated with greater adiposity in later childhood [152]. Maternal nutrition is a major factor
leading to epigenetic changes. Thus, the levels of vitamins consumed in pregnancy such as
folate, methionine and vitamin B12, which affect methylation, become very important [147].
One study showed that prenatal exposure to malnutrition can determine abnormal DNA
methylation resulting in epigenetic modifications that remain for the whole existence and that
predispose to obesity and metabolic and cardiovascular risk in later life [153]. On the other
hand also glycemic status during pregnancy is an important factor; in fact, hyperglycemia, as
well as having a strong impact on the child's weight, can increase the risk of developing insulin
resistance and obesity [147].
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6. Steatosis and genetic of steatosis
Non‐alcoholic fatty liver disease (NAFLD) actually represents the most frequent cause of
chronic liver disease in industrialized countries in children and adolescents, as a direct
consequence of the rise in childhood obesity [154]. Italian epidemiological data indicate that
NAFLD affects approximately 3–10% of general pediatric population. This percentage
increases up to >70%, with a male‐to‐female ratio of 2:1, in obese children [155]. NAFLD is
defined by hepatic fat infiltration >5% hepatocytes, in the absence of other causes of liver
pathology (such as daily alcohol utilization and either viral, autoimmune or drug‐induced
liver disease). It includes a spectrum of disease ranging from intrahepatic fat accumulation
(steatosis) to various degrees of necrotic inflammation and fibrosis (non‐alcoholic steatohepa‐
tatis [NASH]); simple steatosis has generally a benign course, but, rarely in children, NASH
may progress to advanced and severe liver damage like cirrhosis and its complications
(hepatocellular carcinoma and portal hypertension) [154, 156].
The pathogenesis of NAFLD appears to be multifactorial. The principal risk factor for fatty
liver in childhood is obesity, but several other factors contribute to NAFLD development,
including race/ethnicity, genetic factors, environmental exposures and alterations in the gut
microbiome [157]. The dramatic rise in the prevalence of pediatric NAFLD is closely associated
with the epidemic of obesity and metabolic syndrome; as in adulthood, pediatric NAFLD is
associated with severe metabolic impairments such as insulin resistance, hypertension and
abdominal obesity, determining an increased risk of developing type 2 diabetes mellitus, the
metabolic syndrome and cardiovascular diseases [157, 158]. In addition, unhealthy food
choices and the excessive fructose consumption in particular the fructose contained in the most
common soda can promote the development of fatty liver [159].
The prevalence of hepatic steatosis varies among different ethnic groups. The ethnic group
with the highest prevalence is the American Hispanic one (45%) followed by the Caucasian
(33%) and the African‐American (24%). The fatty liver prevalence in Europe, Australia and
Middle East encompasses from 20 to 30%. In India, the fatty liver prevalence in urban popu‐
lations encompasses from 16 to 32%; but in rural India, where there are traditional diets and
lifestyles, the prevalence is lower (about 9%); this evidence suggests that a sedentary lifestyle
and globalization of Western diet could be associated with an increase in the fatty liver
prevalence in developing nations. In all the ethnicity, NAFLD is more prevalent in boys than
in girls with a male to female ratio of 2:1 [160, 161].
Regarding to genetic factors, one of the most important gene involved in determining hepatic
steatosis is the patatin‐like phospholipase‐containing domain 3 gene (PNPLA3). Genome‐wide
association studies and other pediatric studies have revealed that the rs738409 (I148M) variant
for PNPLA3 confers susceptibility to NAFLD‐promoting hepatic accumulation of triglycerides
and cholesterol by inhibition of triglyceride hydrolysis [162]. In addition, a recent case‐control
study has demonstrated that the rs9939609A allele of the fat mass and obesity‐associated gene
(FTO) increases the risk of NAFLD [157].
Another gene that acts together with PNPLA3 in determining hepatic steatosis is the glucoki‐
nase regulatory protein (GCKR) gene which encodes for the glucokinase regulatory protein
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(GCKRP) that inhibits the glucokinase (GCK) activity competing with the glucose, substrate
of GCK. It has been demonstrated that the GCKRP L466 variant encodes for a protein that
indirectly increased GCK activity. This increase in GCK hepatic activity promotes hepatic
glucose metabolism, raises the concentrations of malonyl coenzyme A, a substrate for de novo
lipogenesis, and contributes in liver fat accumulation [160, 163]. In addition, a study conducted
in Chinese children has shown that that the polymorphism rs11235972 of the uncoupling protein
3 (UCP3) gene is associated with the occurrence of NAFLD. UCP3 is a mitochondrial protein
with a highly selective expression in skeletal muscle, a major site of thermogenesis in humans.
Genetic variants of UCP3 have been associated with NIDDM and obesity [164].
Apolipoprotein C3 gene (APOC3) rs2854117 and rs2854116 variants and farnesyl‐diphosphate
farnesyltransferase 1 (FDFT1) gene rs2645424 variant have been also associated with NAFLD in
adult [160]. Also in the recent years, genetic studies have demonstrated that single‐nucleotide
polymorphisms (SNPs) in genes involved in lipid metabolism (Lipin 1, LPIN1), oxidative
stress (superoxide dismutase 2, —SOD2), insulin signaling (insulin receptor substrate‐1, IRS‐1) and
fibrogenesis (Kruppel‐like factor 6, KLF6) have been associated with a high risk for NAFLD
development and progression [154]. Finally, a recent study evaluated the combined effect of
four‐polymorphisms genetic risk score in predicting NASH in NAFLD obese children with
increased liver enzymes to help NASH diagnosis with the other non‐invasive diagnostic tests
[165].
In conclusion, obesity and fatty liver disease often go hand in hand even in the pediatric
population, and both are pathologies related to genetic and environmental factors.
7. Genetic approach to obesity
Recognizing the monogenic syndromic and not syndromic obesity is really very important for
at least two reasons: firstly, because it is hoped that, in the near future, making use of the results
of other research in the field of obesity, obese patients can benefit from specific treatment (such
as leptin administration and MC4R receptor agonists); secondly, because it is hoped that they
will benefit from a multidisciplinary approach to the management of the symptoms, however,
the clinical features of patients with genetic obesity are often very blurred, so that diagnosis
can escape at first. Figure 5 shows a diagnostic classification algorithm which can be useful in
territorial pediatrics to suspect monogenic obesity and in the second and third levels in
hospitals to orientate themselves in the execution of all the diagnostic tests in order to confirm
the final diagnosis [12].
The genetic contribution to common obesity has been established initially through family, twin
and adoption studies. Twin studies have shown a relatively high heritability ranging from 40
to 77% [6]. Gene identification for the last 15 years has been based on two genetic epidemio‐
logical approaches (candidate gene and genome‐wide linkage methods). Recently, genome‐
wide association studies have brought great information on obesity‐related genes.
Candidate‐gene studies: The design of the candidate gene approach is simple; candidate genes
are genes that, according to their characteristics, can be considered causally related to the
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disease. This method is based on the following resources: animal models using gene knockout
and transgenic approaches and cellular model systems showing their role in metabolic
pathways involved in glucose metabolism. There are two main types of candidates that are
generally considered in such studies: functional and positional. Functional candidates are
genes with products that are in some way involved in the pathogenesis of the disease.
Positional candidates are genes that are identified because they lie within genomic regions that
have been shown to be genetically important in linkage or association studies, or by the
detection of chromosomal translocations that disrupt the gene [2, 3]. The latest update of the
Human Obesity GeneMap reported 127 candidate genes for obesity‐related traits. Results of
large‐scale studies suggest that obesity is strongly associated with genetic variants in the MC4R
gene, adrenergic β3 receptor (ADRB3) gene, PCSK1 gene, BDNF gene and endocannabinoid receptor
1 (CNR1) gene [16].
Genome‐wide linkage studies: Genome‐wide linkage studies (GWLS) identify new, unforeseen
genetic variants associated with a disease or a feature of interest. They rely on kinship of study
participants and seek to identify chromosomal regions that tend to be co‐inherited by indi‐
viduals. The limit of genome‐wide linkage studies is that they have a rather coarse resolution
and typically identify broad intervals that require follow‐up genotyping to pinpoint the genes
that underlie the linkage signal [17]. The latest Human Obesity Gene Map update reported 253
loci from 61 genome‐wide linkage scans, of which 15 loci have been replicated in at least three
studies [16].
Genome‐wide association studies: Genome‐wide association studies (GWAS) are used in genetic
research to look for associations between many (typically hundreds of thousands) specific
genetic variations (more commonly, single‐nucleotide polymorphisms, SNP) and particular
diseases or traits. Genome‐wide association studies have a higher resolution levels and are
Figure 5. Diagnostic approach to genetic obesity. Adapted with permission from Farooqi and O'Rahilly [12].
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able to narrow down the locus associated with greater accuracy, so this approach took place
in the genome‐wide linkage studies for common disease [3]. This new approach has found
about 30 loci associated with obesity and high BMI. The strongest association is with FTO gene
(the fat‐mass and obesity‐related gene) mutations. Also BDNF, SH2B1 e NEGR1 mutations are
associated with obesity and support that obesity is a disorder of hypothalamic function [17].
Since the beginning of the genome‐wide association study (GWAS) era in 2005, a number of
large GWASs have been conducted on obesity‐related traits in humans. A large meta‐analysis
from 46 studies conducted by the Genetic Investigation of Anthropometric Traits (GIANT)
[166] consortium identified 32 SNPs robustly associated with adult BMI. The majority of these
SNPs demonstrated directionally consistent effects in age‐ and sex‐adjusted BMI in children
and adolescents. However, even in combination, the 32 established SNPs explain <2% of the
variation in BMI in either adults or children. The mismatch between the high heritability
estimates from twin and other family studies (40–70%) and the small percentage of variation
explained through GWAS (<2%) is called the problem of “missing heritability” [167, 168]. A
portion of the missing heritability appears to be due to rare genetic variants and some non‐
additive genetic effects that are not found in analyses GWAS that showed only additional
effects of common SNPs with minor allele frequencies (MAF) of >5%. Another part of the
missing heritability can be explained by the fact that multiple additional common genetic
mutations contribute to obesity, but they have a small effect that cannot be found by GWAS
analyses [168].
New types of analyses, such as genome‐wide complex trait analysis (GCTA), analysis of
uncommon (MAF 0.5–1%) or rare (MAF 0.5%) variants and structural variants not detected by
GWAS arrays, epigenetic analysis and gene–gene interactions (epistasis), are helping to fill that
gap [167]. The purpose of the novel approach called genome‐wide complex trait analysis
(GCTA) is not to identify specific SNPs related to the target phenotype, but rather to estimate
the total additive genetic effect of the common SNPs used on currently available DNA arrays
[168].
The rare variant—common disease hypothesis—suggests that rare variants contribute signifi‐
cantly to complex traits. Probably, the obese phenotype is the consequence of additive effects
and interactions among multiple alleles with varying magnitude of effect. Actually, we know
that only 1% of the human genome is transcribed into mRNA and translated into proteins. An
additional 0.5% is regulatory regions that control gene expression. Functions of the remaining
98.5% of the genome remain unknown. Rare variants might be identified by massive genotyping
or deep sequencing in large families thanks to novel techniques that sequence millions of DNA
strands in parallel and at low cost such as next‐generation sequencing techniques [169].
Copy number variants (CNVs) represent another source of the heritability that is missed by
GWAS studies. Copy number variants (CNVs) are products of genomic rearrangements,
resulting in deletions, duplications, inversions and translocations [167, 170]. The most
established CNV in the obesity field is a large, rare chromosomal deletion at 16p11.2; this
deletion includes a small number of genes, one of which is SH2B1, known to be involved in
leptin and insulin signaling. The search for CNVs in the context of obesity has proved fruitful,
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and it has become quite clear they play a role in the missing heritability that still needs to be
explained for the disease [19, 170].
8. Treatment options in patients with genetic obesity
The use of pharmacologic treatment for obesity is recommended by the American Academy
of Pediatrics (AAP) as an adjunct to lifestyle changes when obesity‐related health risks exist
and lifestyle changes have not been effective for an individual. In addition, the AAP recom‐
mends pharmacotherapy only for children with BMI ≥99th percentile [171]. On the other hand,
the Endocrine Society has suggested limiting pharmacotherapy to patients with a BMI over
the 95th percentile who have failed diet and lifestyle intervention, or in limited cases with a
BMI over the 85th percentile and severe comorbidities [147]. Overweight children should not
be treated with pharmacotherapeutic agents unless significant, severe comorbidities persist
despite intensive lifestyle modification. In these children, a strong family history of NIDDM
or cardiovascular risk factors strengthens the case for pharmacotherapy [172].
There are currently only a few drugs approved for the treatment of obesity; such drugs belong
to different pharmacologic categories with different mechanisms of action. A major class of
medications used in weight treatment is appetite suppressants also called anorexigenic agents.
These drugs increase hypotalamic levels of norepinephrine, dopamine and serotonin‐promot‐
ing satiety and decreasing hunger [173]. Among the appetite suppressant drugs, sibutramine
was used to treat obesity in children until recently. In 2010, sibutramine was withdrawn by the
United States Federal Drug Administration (US FDA) and European Medicine Agency (EMA)
for increased cardiovascular risk for individuals taking the medication [174]. As well, other
drugs of the same class like ephedrine and fenfluramine were withdrawn from the market for
their adverse effects [147]. With the withdrawal of sibutramine, orlistat and metformin are now
the only available drugs for the treatment of pediatric obesity.
Orlistat, an inhibitor of pancreatic lipases, prevents the breakdown of triglycerides into
absorbable fatty acids and monoglycerols. Thus, about one‐third of the dietary intake,
triglycerides is not absorbed. It reduces body weight, total cholesterol and LDL cholesterol,
and the risk of NIDDM in adults with abnormal carbohydrate metabolism. In USA, orlistat is
approved by the FDA in adolescents older than 12 years [175]. It is associated with a significant
fall in BMI of 0.7 kg/m2, but treatment is associated with increased rates of side effects including
abdominal discomfort, pain, steatorrhoea and decreased absorption of the fat‐soluble vitamins
A, D, E and K. So, it is important to take those fat‐soluble vitamins supplementation 2‐h
distance from orlistat administration [147]. Side effects are usually mild to moderate and
generally decrease in frequency with continued treatment; this decrease may result from
patients learning to consume less dietary fat to avoid these side effects. Typically, doses of
120 mg by mouth three times daily are needed for effectiveness [176, 177].
Although metformin has not been approved by the US FDA for the treatment of obesity, it may
be effective as a weight loss agent in addition to its effects as a hypoglycemic agent. Its major
site of action is the liver: the drug increases glucose uptake, decreases hepatic gluconeogenesis
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and reduces hepatic glucose production; also, metformin inhibits lipogenesis and increases
insulin sensitivity and may have an effect as an appetite suppressant. The major benefits of the
medication are reduction of food intake, weight loss, visceral fat reduction, improvement of
the lipid profile and of the carbohydrate intolerance [172, 175, 178]. A systematic assessed five
randomized controlled trials all with follow‐up of at least 6 months; compared to placebo,
metformin reduced BMI by 1.42 kg/m2 in obese children [179]. Patients treated with metformin
report abdominal discomfort, which improves when the drug is taken with food. There is also
a risk of vitamin B12 deficiency; therefore, a multivitamin is recommended. The risk of lactic
acidosis has been observed in adults but not seen in pediatric patients [147].
Octreotide, a somatostatin analogue, has been investigated as a treatment for hypothalamic
obesity. It binds receptors on the beta cells of the pancreas and inhibits insulin release [147]. A
study comparing octreotide with placebo has demonstrated statistically significant weight loss
and statistically significant mean decreases in BMI among those treated with octreotide for 6 
months [180]. Octreotide works better in patients with insulin hypersecretion and insulin
resistance. A study has demonstrated that greater weight loss correlated with a greater degree
of insulin hypersecretion [181]. The high cost of the drug and the various side effects (gastro‐
intestinal problems, gallstones, GH and TSH suppression, cardiac dysfunction) limit currently
use [175].
In the case of monogenic obesity, subcutaneous injection of recombinant human leptin in
children and adults with LEP mutations resulted in weight loss, mainly of fat mass, with a
major effect on reducing food and hyperphagia, induction of puberty (even in adults) and
improvement in T‐cell responsiveness [24, 25, 27, 182]. Leptin treatment works in patients with
leptin deficiency or with bioinactive leptin, but on the other hand, leptin treatment is useless
in LEPR‐deficient subjects, because the receptor mutations make it inactive [24, 183].
In the case of children with PWS, GH therapy can improve growth, body composition, muscle
thickness, physical strength and agility, motor performance, fat utilization, and lipid metabo‐
lism [184–186]. The best response to GH in PWS patients is observed in the first 12 months of
treatment. Although early treatment is important for the improvement in body composition,
generally, in practice, it is possible to start treatment only after 2 years of age. Treatment can
be started in a dose of 0.034 mg/kg/day (0.24 mg/kg/week) in infants, and toddlers and IGF‐1
and IGFBP‐3 levels are used to specify the dose of GH therapy. Benefits of continuing GH
therapy in adulthood remain unclear although an improvement has been observed in body
composition and cognitive functions in patients who received treatment only in adulthood.
Contraindications for GH therapy in PWS patients are severe obesity, uncontrolled diabetes
mellitus, untreated severe OSA, active cancer and psychosis [108].
A number of the PWS features, such as hyperphagia, obesity and behavioral anomalies, may
be due to consequent hypothalamic hyposecretion of oxytocin for the reduction of paraven‐
tricular nucleus neurons. A few studies have investigated the capacity of exogenous oxytocin
to improve these PWS features, but other research is necessary [183].
For MC4R‐deficient obese patients, currently, there are no specific treatments. Different MC4R
agonists were studied in vivo in animal and human studies, and almost all studies are currently
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in the preclinical phase. These pharmacological MC4R agonists can restore normal activity in
mutated receptors, and in obese animal, models cause decreased food intake, increased total
energy expenditure, weight loss and weight‐independent improvement of insulin sensitivity
after 8 weeks of treatment [43, 187].
Finally, most recent studies on the treatment of obesity have focused on the potential role of
plants used for obesity and its metabolic disorders treatments, exerting a positive effect on
lipid and glucose metabolism, and anti‐inflammatory activity [188]. For example, green tea
disclosed anti‐obesity effects in both in vitro and in vivo, decreasing adipose tissue through the
reduction of adipocytes differentiation and proliferation, showing a positive effect in lipid
profile, and lipid and carbohydrates metabolisms, and anti‐inflammatory activity [188].
However, in literature, the anti‐obesity properties and the mechanisms of action of some plants
such as Camellia sinensis, Hibiscus sabdariffa, Hypericum perforatum, Persea americana, Phaseolus
vulgaris, Capsicum annuum, Rosmarinus officinalis, Ilex paraguariensis, Citrus paradisi, Citrus limon,
Punica granatum, Aloe vera, Taraxacum officinale and Arachis hypogea have been described [188].
However, polysaccharide macromolecules slowing the rate of carbohydrate and fat absorption
have been also described reduce insulinemic peaks, enhancing β‐cell function and potentially
restoring the insulin secretory reserve in patients with impaired glucose tolerance or NIDDM
and genetic obesity history [189].
Another possible therapy for childhood obesity is bariatric surgery. There are 3 types of
bariatric procedures: malabsorptive, restrictive and combination procedures. The first proce‐
dures are the jejunoileal bypass and the biliopancreatic diversion with duodenal switch that
manage to lose weight by reducing nutrient absorption through the gut anatomical rearrange‐
ments; however, these procedures are not approved in children for their high morbidity and
mortality. The Roux‐en‐Y gastric bypass (RYGB) is a combination procedure; it has become the
most commonly performed bariatric surgical procedure, and it involves a reduction of stomach
size and the reduction of intestinal absorptive capacity via the creation of a gastrojejeunal
anastomosis [171, 172, 190]. Laparoscopic adjustable gastric banding (LAGB) is a wholly
restrictive procedure, and it has been used more recently. This bariatric procedure is to place
a balloon around the esophagogastric junction and inflate it with saline until you get the
desired effect of the stomach size reduction. This procedure is recommended in children
because it is reversible and does not create permanent intestinal rearrangements [171, 172,
191]. Laparoscopic sleeve gastrectomy (LSG) is a new and attractive option for young patients.
It is a new restrictive procedure without the malabsorptive component present in other
bariatric procedures. This technique involves the removal of a large portion of the stomach
through a vertical resection, and the remaining stomach has a volume drastically reduced, with
a capacity of around 100/150 ml. Weight loss outcomes in some study were similar between
pediatric and adult patients at all time points, suggesting that LSG is similarly safe and effective
in young and adult patients through at least 1 year of follow‐up [192].
The criteria for access to bariatric surgery in childhood are very restrictive: BMI >35 kg/m2
with severe comorbidities or >40 kg/m2 with comorbidities, Tanner stage 4 or 5, to achieve at
least 95% of the growth estimate in the case of malabsorptive procedures, the ability to follow
the post‐operative diet and exercise, an adequate social support, ability to follow constantly
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medical indications and treatment and appropriate treatment of psychological problems
[190]. Also it is recommended that bariatric surgery be done only in centers that can provide a
multidisciplinary pre‐ and post‐operative evaluation and psychological support both before
and after the surgery [193].
Currently, data on bariatric surgery in children and adolescents with genetic obesity are limited
and still controversial [183]. To date, bariatric surgery experience in treating children and
adolescents with monogenic and syndromic forms of obesity is limited, and different bariatric
procedures have been used with varying success [194]. Some studies have demonstrated the
efficacy of bariatric surgery (in terms of weight loss and reduction of comorbidities such as
obstructive sleep apnea, dyslipidemia, hypertension, diabetes mellitus and poor mobility) in
patients with monogenic obesity (such as LEPR‐deficient patients and patients with hetero‐
zygous MC4R mutations, but not in patients with homozygous MC4R mutation [195]) and
syndromic obesity (such as PWS, BBS, Alström syndrome) but, due to the limited number of
cases, the long‐term efficacy and safety of bariatric surgery in genetic forms of obesity need
further evaluation [183].
Even more in the early days are studies that try to correlate specific polymorphisms with
response to bariatric surgery: For example, a study tried to find the presence of an association
between several polymorphisms (including the FTO and MC4R genes) with post‐operative
weight loss [196]; another study found that a 15q26.1 locus is significantly associated with
weight loss after Roux‐en‐Y gastric bypass surgery [197]. Thus, there is some evidence for the
use of genomics to identify response to surgical procedures; the identification of genetic
contributors could be useful to select those individuals who will obtain a greater benefit from
a bariatric surgery. However, these results have yet to be confirmed.
9. Hyperphagia: etiopathogenesis and treatment
In the modern environment of plenty, obesity is favored by biological features that generally
are advantageous in a restrictive environment, such as attraction to palatable and energy dense
foods, slow satiety mechanisms and high metabolic efficiency [198].
The control of food intake and energy expenditure consists of a complex network of neural
and hormonal systems that involving many genes [199]: in particular, the informations are
collected at the peripheral level (intestine, stomach, adipose tissue); then, they are processed
at the hypothalamic level and, finally, generate behavioral, endocrine and autonomic output
[198].
In particular, much larger portions of the nervous system of animals and humans, including
cortex, basal ganglia, and the limbic system, are concerned with the procurement of food as a
basic and evolutionarily conserved survival mechanism to defend body weight [200]. These
systems are directly and primarily involved in the interactions of the modern environment
and lifestyle with the human body [198]. By focusing on the neural reward systems and the
interaction between reward and homeostatic functions, it is possible to infer that the disturb‐
ance of this relationship determines obesity (Figure 6).
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This process can generate hedonic and metabolic consequences, which are independent from
each other: in particular, the hedonic consequences are regulated by reward functions while
the metabolic consequences of food (defined in terms of their input of energy and their effects
on body composition, particularly increased fat accretion as in obesity) are regulated by
homeostatic functions.
The alteration of reward functions may be a cause (i.e., excessive caloric intake modulated by
hedonic value of food (1)) and/or a consequence (induced by obese state (3)) of obesity [198].
As schematically depicted in Figure 6, several potential interactions exist between food reward
and obesity.
In particular, there are three fundamental mechanisms involved in the development of obesity,
which are not mutually exclusive, but a combination of all three is operative in most individ‐
uals: excessive intake of palatable and energy dense foods, differences (genetic and other pre‐
existent) in reward functions and increase of obese state consequently to alterations of reward
functions induced by obesity [198].
It is also important to realize that hyperphagia is not always necessary for obesity to develop,
as the macronutrient composition of food can independently favor fat deposition.
In this regard, there is the “gluttony hypothesis” emerged from several studies in animals: in
particular, although reward functions are not altered unlimited access to palatable food and
Figure 6. Relationship between metabolic and hedonic controls of food intake and energy balance. Adapted with per‐
mission from Berthoud et al. [198].
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food cues leads to excessive caloric intake (hedonic overeating) and, consequently, to obesity
(defined as diet‐induce obesity) [198].
However, it is important to underline that not all individuals exposed to environment of plenty
show an increased food intake and weight gain; this means that there are genetic and epigenetic
pre‐existing alterations that make some individuals more vulnerable to the increased availa‐
bility of palatable food and food cues [198].
One of the key questions is how the motivation to get a reward will translate into action. In
most cases, the motivation for something comes from the pleasure that this has generated in
the past, or in other words, to obtain what has been helpful. The dopamine signal seems to be
a critical component in this process [198].
The limited information available suggests that repeated sucrose access can upregulate
dopamine release [201] and dopamine transporter [202] and change dopamine D1 and D2
receptor availability [201] in the nucleus accumbens.
As demonstrated by some observations, such pleasing foods have a high potential for addiction
for which the withdrawal from it can cause symptoms such as anxiety, stress, depression
resulting behavior of relapse because of occurring neural and molecular changes. Therefore,
it is critical for switching the cycle of addiction and the prevention of a further spiral of
addiction [198].
An issue on which to focus is that excessive caloric intake, as part of a disease, can gradually
worsen: in fact at the beginning, there is overeating; then, the individual eats also in the absence
of physiological hunger. Subsequently, there will be loss of control over eating (binge eating),
and finally, hyperphagia defined as a hallmark of inherited disorders, in which obesity is
present [203].
The term “hyperphagia” includes a series of conditions, such as binge eating disorder,
hormonal imbalances such as glucocorticoid excess, leptin signaling abnormalities, syndromes
associated with obesity and cognitive impairment (e.g., PWS) [203] and can be used in different
situations: for example, to evaluate hunger and satiety through appropriate scales for patho‐
logical individuals compared to healthy individuals [203], to evaluate excessive caloric intake
and the impact on body size and body composition in pathological individuals [203] or to
evaluate preoccupation and psychological symptoms such as anxiety, stress due to hyperpha‐
gic behavior and the consequences that it determines (e.g., continuous search for food, night
eating, ingestion of inedible food, theft of food, etc.) [203].
A person with hyperphagia has an obsessive and compulsive behavior towards food and often
continues to eat for a long time, even if he/she feels full. This excessive nutriment can cause
abdominal pain, guilt or drowsiness.
In particular, obesity is associated with dysregulated signaling systems, such as leptin and
insulin resistance, as well as increased signaling through proinflammatory cytokines and
pathways activated by oxidative and endoplasmatic reticulum stress [204] (Figure 7).
As schematically depicted in Figure 7, obesity and, in turn, neurodegenerative diseases may
be caused by leptin resistance, central insulin and altered regulation of energy balance, con‐
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trolled by hypothalamus. About the latter, the literature shows that mitochondrial and oxida‐
tive stress increase due to high‐fat diets leading to neural/glial dysfunction and, consequently,
cytotoxic effects [198].
However, these toxic effects do not stop at the level of the hypothalamus but can also affect
brain areas involved in reward processing [198].
10. Nutritional and behavioral approach to genetic obesity
The approach to the child with genetic obesity is very complex considering that obesity is
associated with a number of complications that include the health of the child, and it must be
focused on the entire family. Awareness about the problem by all family members and, in
particular, changes in lifestyle and nutrition of the family are the most effective means both to
ensure the compliance to the treatment, the success of the therapy and the maintenance of the
long‐term results.
The family, especially the parents, should be actively involved in the therapeutic program and
become protagonists. The targeted intervention with “individual” programs only for the child,
on the contrary, is often unsuccessful and frustrating for the child himself [205].
According to NICE guidelines on weight management in children dating from 2014 [206], it is
important to:
• coordinate the care of children and young people around their individual and family needs
[206];
• assess and intervene to improve child's health, considering his age and maturity. It is
important to set goals based on needs and preferences both of the child that of the whole
family [206];
Figure 7. Secondary effects of obesity on reward circuitry and hypothalamic energy balance regulation. Adapted with‐
permission from Berthoud et al. [198].
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• create an environment that promotes lifestyle changes within the family and in social
settings. Parents (or carers) are responsible of these changes, especially if children are
younger than 12 years old [206].
The initial assessment is important to collect data necessary for diagnosis and subsequent
treatment. In particular, these informations regarding patient history (personal, familiar,
healthy and social history), food/nutrition‐related history (eating patterns, diet experience,
physical activity, beliefs and attitudes about eating, etc.), anthropometric measures (current
weight, weight history, etc.), biochemical data and medical tests (e.g., lipid profile, glucose
profile, etc.); what the person has already tried and how successful this has been will be
discussed, and what they learned from the experience; the person's readiness to adopt changes
and their confidence in making changes will be assessed [206].
Multicomponent interventions are the treatment of choice. Weight management programs
must include behavior change strategies to increase people's physical activity levels or decrease
inactivity, improve eating behavior and the quality of the person's diet and reduce energy
intake [206].
In particular, nutrition offered to obese children must also ensure the maintenance of adequate
rhythms of growth and promote the maintenance of lean body mass (in particular of muscle
mass), which represents the metabolically active compartment, and it is the large part of the
total energy expenditure. Therefore, it must necessarily guarantee the macro‐ and micro‐
nutrients intake in relation to their age [205].
In overweight and obese children and young people, it is important a multidisciplinary
intervention that includes dietary recommendations appropriate for age and complies with
the principles for a healthy nutrition (in these patients, total energy intake should be below
their energy expenditure) [206].
Dietary changes should be tailored to food preferences and allow for a flexible and individual
approach to reducing calorie intake; it is important not to use unduly restrictive and nutri‐
tionally unbalanced diets because they are ineffective in the long term and can be harmful [206].
In these patients, it is also necessary that an intervention about physical activity is important
not only for lose weight, but also for other health benefits, such as reduction risk of type 2
diabetes or heart diseases [206].
Therefore, obese and overweight children must be encouraged to become more active and to
reduce inactive behaviors, such as sitting and watching television, using a computer or playing
video games and to do at least 60 min of moderate or greater intensity physical activity each
day. The activity can be in 1 session or several sessions lasting 10 min or more [206].
It is important to make the choice of activity with the child and ensure that it is appropriate to
the child's ability and confidence, giving children the opportunity and support to do more
exercise in their daily lives (e.g., walking, cycling, using the stairs and active play) or to do
more regular, structured physical activity (e.g., football, swimming or dancing) [206].
Children affected by genetic obesity (e.g., PWS) often eat more than necessary for anxiety,
sadness, boredom: in this case, it is important not only to reduce the amount of foods but also
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to search for reasons of suffering causing the overeating. It is important, therefore, to recon‐
struct the individual's self‐esteem [206].
There are, however, barriers to parental involvement in the child's treatment: in some families,
for cultural or psychological reasons, parents do not perceive their child as obese. In other
families, parents may acknowledge that the child is obese but denies that this condition can
have consequences.
Therefore, it is crucial to raise awareness among parents of the need to intervene, especially
when behavioral changes are needed in the family [207].
Focusing on hyperphagic children, particularly those affected by Prader–Willi syndrome,
parents must learn to celebrate each small goal, large or small, and to appreciate the acquisition
of any new skill [208].
In these children, there are behavior changes that become more apparent and severe with age:
in fact, they are concerned about food, hypersensitive, agitated, aggressive, impulsive, anxious.
These behaviors are caused specially by their insatiable appetite that causes physical, emo‐
tional and social problems [209].
For these reasons, it is important to intervene to reduce stress not only for children, but also
for the whole family.
However, to control the anxious behavior in children with PWS, the following information
may be useful:
• having a regular daily routine, following appropriate food program;
• giving your child transitional warnings—that is, “after you finish that puzzle, it is time for
bath” [209];
• preparing your child ahead of time if there is going to be a change in routine;
• re‐directing your child to another activity;
• using positive reinforcement;
• speaking to your child in a calm, yet firm matter‐of‐fact tone [209].
In children with PWS, it is essential management food, based also on control food access, to
ensure adequate nutrition, weight regulation and appropriate eating behaviors.
Crucial in this regard is the role of parents, who must support their children in these changes
by adopting appropriate strategies.
However, each family will find the best way for them and for the specific need of their child.
First of all, it is important to follow an adequate food program that helps parents to monitor
their food intake and reassures the child that the food will always be available: therefore, it
represents the beginning for him to acquire the habit of eating healthy so that food can be
controlled and could become a part of his daily routine [209].
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This program is based on three main meals (breakfast, lunch, and dinner) and two or three
snacks (mid‐morning snack, afternoon snack, and perhaps evening snack) [209]. It is funda‐
mental to respect scheduled times (food must be given every 2–3 h), avoiding giving food
outside mealtimes. Whenever possible, all family members should eat at the same time and
others should not eat in front of the child when it is not their scheduled meal/snack time [209].
Portion control is another adequate strategy: it must not be excessive, but appropriate for the
child's age to ensure adequate growth [209].
However, food must be healthy considering that in children with PWS, calorie needs are lower
due to reduced metabolism. Food must be given only by parents/caregivers and served on the
plate prior to being eaten, avoiding other platters/bowls of food visible on the table and to
share or offer them other food [209].
At the end of the meal, it is important to remove the empty plate from the table and encourage
the child to play away from the table or from the kitchenette until all food has been taken away.
It is important to keep food out of sight and reach of children, keeping it under lock and key
if necessary [209] (Figure 8).
Figure 8. Girl with Bardet‐Biedl syndrome. You can see the amelioration of the BMI after the interdisciplinary ap‐
proach to hyperphagia.
11. Conclusions
This chapter may bring a significant contribution to the updating of knowledge of the genetic
susceptibility and provide a better clarification of which variants are truly associated with the
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predisposition to develop an obese phenotype. This chapter may also help to understand better
the genetic diversity that could be associated in subjects with genetic forms of obesity.
However, this chapter may help to understand this complex problem and the different
approaches to treatment. In these forms of genetic obesity, the team approach to therapy (nurse
educators, nutritionists, exercise physiologists, and counsellors) is the basis for treatment.
Dramatic reductions in BMI are difficult to achieve and sustain, so counselling and therapy
should start with realistic goals that emphasize gradual reductions of body fat and BMI and
maintenance of weight loss. Finally, this chapter may provide news on the need for new
therapeutic approaches in the field of childhood obesity as the basis of the hyperphagia
treatment, a typical feature of these syndromes.
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